May 4, 2022
Life Sciences
  • Biogen Inc. will effectively end marketing for its controversial Alzheimer’s disease drug Aduhelm after sales reached $2.8 million in the first quarter, just 0.1 percent of its product sales. Chief Executive Michel Vounatsos will also leave Biogen as the company seeks to move on from the Aduhelm fallout. (Articles here and here)